-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $3

Benzinga·04/22/2026 09:59:21
Listen to the news
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $5.5 to $3.